2-year survival data from a randomized study of peginterferon alfa-2a (40KD) vs interferon alfa-2a in patients with chronic-phase chronic myelogenous leukemia.

被引：0
|
作者：
Lipton, JH
Khoroshko, ND
Golenkov, AK
Abdulkadyrov, KM
Nair, MK
Raghunadharao, D
Brummendorf, T
Bergstrom, B
机构：
[1] Princess Margaret Hosp, Allogene BMT Program, Toronto, ON M4X 1K9, Canada
[2] Hematol Res Ctr, Dept Leucosis, Chemotherapy & Pathol Erithron, Moscow, Russia
[3] Moscow Regional Res Clin Inst, Dept Hematol Immunol, Moscow, Russia
[4] Russian Sci Res Inst Hematol & Transfusiol, Dept Hematol, St Petersburg, Russia
[5] Reg Canc Ctr, Dept Med Oncol, Trivandrum 695011, Kerala, India
[6] Nizams Inst Med Sci, Dept Med Oncol, Hyderabad, Andhra Pradesh, India
[7] Univ Tubingen, Med Klin Poliklin, Dept Hematol Oncol Immunol & Rheumatol, Tubingen, Germany
[8] Hoffmann La Roche Inc, Nutley, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3363
引用
收藏
页码：904A / 904A
页数：1
相关论文
共 50 条
  • [1] A randomized multicenter comparative study of peginterferon alfa-2a (40KD) vs interferon-alfa-2a in patients with treatment-naive chronic-phase chronic myelogenous leukemia.
    Lipton, JH
    Khoroshko, ND
    Golenkov, AK
    Abdulkadyrov, KM
    Nair, MK
    Raghunadharao, D
    Brummendorf, T
    Hooftman, L
    BLOOD, 2002, 100 (11) : 782A - 782A
  • [2] Peginterferon alfa-2a (40KD): A potent long-acting form of interferon alfa-2a for the treatment of hepatitis C
    Modi, MW
    Lamb, MW
    Shiomi, M
    POLYMER DRUGS IN THE CLINICAL STAGE: ADVANTAGES AND PROSPECTS, 2003, 519 : 59 - 67
  • [3] Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
    Preudhomme, Claude
    Guilhot, Joelle
    Nicolini, Franck Emmanuel
    Guerci-Bresler, Agnes
    Rigal-Huguet, Francoise
    Maloisel, Frederic
    Coiteux, Valerie
    Gardembas, Martine
    Berthou, Christian
    Vekhoff, Anne
    Rea, Delphine
    Jourdan, Eric
    Allard, Christian
    Delmer, Alain
    Rousselot, Philippe
    Legros, Laurence
    Berger, Marc
    Corm, Selim
    Etienne, Gabriel
    Roche-Lestienne, Catherine
    Eclache, Virginie
    Mahon, Francois-Xavier
    Guilhot, Francois
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26): : 2511 - 2521
  • [4] Enhanced pharmacokinetics (PK) and pharmacodynamics (PD) of peginterferon alfa-2a (40KD) (PEGASYS®) vs conventional interferon alfa-2a in HBeAg-positive chronic hepatitis B (CHB)
    Choudhury, S
    Wang, YJ
    Thongasawat, S
    Minde, Z
    Chan, WY
    Piratvisuth, T
    Yuan, R
    ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER MEETING 2002, 2002, : 95 - 100
  • [5] The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40KD) in children with chronic hepatitis C
    Schwarz, KB
    Mohan, P
    Narkewicz, M
    Molleston, JP
    Te, HS
    Hu, S
    Sheridan, S
    Lamb, M
    Pappas, SC
    Harb, G
    GASTROENTEROLOGY, 2003, 124 (04) : A700 - A700
  • [6] Combination of Levovirin (LVV) and peginterferon alfa-2a (40 KD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40KD) in patients with chronic hepatitis
    Pockros, PJ
    Pessoa, MG
    Diago, M
    Martinelli, ADC
    Berg, T
    Germanidis, G
    Lai, MY
    Gomez, HR
    Goeser, T
    Roberts, S
    Sheen, IS
    Hsien, T
    Hinrichsen, HM
    Lee, SS
    Reindollar, R
    Sola, R
    Wilson, K
    Jorga, K
    Graham, P
    Jackson, H
    HEPATOLOGY, 2004, 40 (04) : 391A - 391A
  • [7] Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    Sherman, M.
    Yoshida, E. M.
    Deschenes, M.
    Krajden, M.
    Bain, V. G.
    Peltekian, K.
    Anderson, F.
    Kaita, K.
    Simonyi, S.
    Balshaw, R.
    Lee, S. S.
    GUT, 2006, 55 (11) : 1631 - 1638
  • [8] ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
    Piratvisuth, T
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Why, RD
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 656A - 657A
  • [9] Predictive factors in treatment of chronic hepatitis c (cHC) patients with peginterferon alfa-2a (40KD) and ribavirin
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Berrid
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A839 - A839
  • [10] Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
12345